| Member | Buys | Sells | Est. net | Last move |
|---|---|---|---|---|
| Gilbert Cisneros CA31 | 7 | +$80.5K | Bought May 4, 26 | |
| Lisa McClain MI09 | 1 | 1 | +$0 | Trimmed Jul 22, 25 |
| Rob Bresnahan PA08 | 1 | 1 | +$0 | Sold Apr 8, 25 |
| April McClain Delaney MD06 | 1 | −$32.5K | Sold Feb 28, 25 |
| Traded | Member | Owner | Type | Amount | Filed | Report |
|---|---|---|---|---|---|---|
| May 4, 26 | Gilbert Cisneros CA31 | Self | Buy | $15,001 - $50,000 | Jun 8, 26 (35d) | |
| May 1, 26 | Gilbert Cisneros CA31 | Self | Buy | $1,001 - $15,000 | May 8, 26 (7d) | |
| Sep 12, 25 | Gilbert Cisneros CA31 | Self | Buy | $1,001 - $15,000 | Oct 10, 25 (28d) | |
| Aug 13, 25 | Gilbert Cisneros CA31 | Self | Buy | $1,001 - $15,000 | Sep 12, 25 (30d) | |
| Jul 23, 25 | Gilbert Cisneros CA31 | Self | Buy | $1,001 - $15,000 | Aug 14, 25 (22d) | |
| Jul 22, 25 | Lisa McClain MI09 | Spouse | Sell (part) | $1,001 - $15,000 | Aug 13, 25 (22d) | |
| Jun 17, 25 | Lisa McClain MI09 | Spouse | Buy | $1,001 - $15,000 | Aug 13, 25 (57d) | |
| Jun 11, 25 | Gilbert Cisneros CA31 | Self | Buy | $1,001 - $15,000 | Jul 10, 25 (29d) | |
| May 28, 25 | Gilbert Cisneros CA31 | Self | Buy | $1,001 - $15,000 | Jun 6, 25 (9d) | |
| Apr 8, 25 | Rob Bresnahan PA08 | Self | Sell | $1,001 - $15,000 | May 8, 25 (30d) | |
| Feb 28, 25 | April McClain Delaney MD06 | Child | Sell | $15,001 - $50,000 | Mar 20, 25 (20d) | |
| Feb 25, 25 | Rob Bresnahan PA08 | Self | Buy | $1,001 - $15,000 | Mar 27, 25 (30d) |
From the House's STOCK Act reports (Senate not included). Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Sep 20, 2026 | Krakowiak MaxwellChief Financial Officer | Sale at price 144.53 per share. | 1.6K | $235.73K |
| Aug 24, 2026 | Michas Alexandros PDirector | Stock Gift at price 0.00 per share. | 285 | — |
| Aug 13, 2026 | Goldberg Joel SGeneral Counsel | Stock Gift at price 0.00 per share. | 27.8K | — |
| Aug 12, 2026 | Singh Prahlad RChief Executive Officer | Stock Gift at price 0.00 per share. | 67.3K | — |
| Jul 19, 2026 | Gonzales AnitaOfficer | Sale at price 109.48 per share. | 85 | $9.31K |
| May 6, 2026 | Witney Franklin R. Ph.D.Director | Stock Award(Grant) at price 0.00 per share. | 2.3K | — |
| May 6, 2026 | Barrett PeterDirector | Stock Award(Grant) at price 0.00 per share. | 2.3K | — |
| May 6, 2026 | Michas Alexandros PDirector | Stock Award(Grant) at price 0.00 per share. | 2.7K | — |
| May 6, 2026 | Vounatsos Michel PericlesDirector | Stock Award(Grant) at price 0.00 per share. | 2.3K | — |
| May 6, 2026 | Chapin Samuel R.Director | Stock Award(Grant) at price 0.00 per share. | 2.3K | — |
| May 6, 2026 | Vandebroek Sophie VDirector | Stock Award(Grant) at price 0.00 per share. | 2.3K | — |
| May 6, 2026 | Witz PascaleDirector | Stock Award(Grant) at price 0.00 per share. | 2.3K | — |
| May 6, 2026 | Klobuchar Michael ADirector | Stock Award(Grant) at price 0.00 per share. | 2.3K | — |
| May 6, 2026 | Mcmurry-Heath MichelleDirector | Stock Award(Grant) at price 0.00 per share. | 2.3K | — |
| Apr 19, 2026 | Gonzales AnitaOfficer | Sale at price 92.80 per share. | 80 | $7.42K |
| Mar 15, 2026 | Gonzales AnitaOfficer | Stock Award(Grant) at price 0.00 per share. | 1.6K | — |
| Mar 5, 2026 | Gonzales AnitaOfficer | Stock Award(Grant) at price 0.00 per share. | 1.7K | — |
| Feb 23, 2026 | Victor MiriameOfficer | Sale at price 97.13 per share. | 1.9K | $180.86K |
| Feb 23, 2026 | Victor MiriameOfficer | Conversion of Exercise of derivative security at price 95.74 per share. | 1.9K | $178.27K |
| Feb 22, 2026 | Mcmurry-Heath MichelleDirector | Sale at price 97.26 per share. | 600 | $58.36K |
Revvity, Inc. provides health sciences solutions, technologies, and services. The company offers instruments, reagents, software, subscriptions, detection and imaging technologies, extended warranties, and training and services; and instruments, reagents, and assay platforms and software products for early detection of common and rare conditions, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. It also develops technologies that enable and support genomic workflows using protein coupled receptors and next-generation DNA sequencing for oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, chemagic, Chitas, CNGnome, DELFIA, DELFIA Xpress, EONIS, EUROArray, EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, GSP, Haoyuan, IDS Immunodiagnosticsystems, IDS-i10, IDS-i10T, IDS-i20, IDS-iSYS, iLab, iQ, LifeCycle, LimsLink, Migele, NeoBase, NeoLSD, NEXTFLEX, Panthera Puncher, PreNAT II, Prime, RONIA, SimplicityChrom, Specimen Gate, Superflex, Symbio, T-SPOT, Vanadis, ViaCord, VICTOR2, and WholePanel brand names, as well as under the Accell, AlphaLISA, AlphaPlex, AlphaScreen, Alpha SureFire, AssayMate, BIOCHIPs, BioLegend, Bioo Scientific, BioQule, Brilliant Violet, Ce3D, CellCarrier, Cellaca, Celigo, Cellometer, cell::explorer, Cell-Vive, Chalice, ChemDraw, CHOSOURCE, Dharmacon, and DharmaFECT brand names. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
Buy / hold / sell counts
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 12.5 | -9.6 | -10.9 | -1.1 | 20.7 | 6.4 | 1.1 | 14.4 | 18.8 | 1.8 | +60.8% | ||
| 2025 | 13.0 | -11.1 | -5.7 | -11.7 | -3.2 | 7.0 | -9.1 | 2.5 | -2.7 | 6.8 | 11.6 | -7.3 | −13.3% |
| 2024 | -1.9 | 2.2 | -4.2 | -2.4 | 6.6 | -4.0 | 19.8 | -2.4 | 4.3 | -7.2 | -2.1 | -3.9 | +2.1% |
| 2023 | -1.9 | -9.4 | 7.0 | -2.1 | -11.6 | 3.0 | 3.5 | -4.8 | -5.4 | -25.2 | 7.3 | 23.0 | −22.0% |
| 2022 | -14.4 | 4.3 | -2.9 | -16.0 | 2.1 | -5.0 | 7.7 | -11.8 | -10.9 | 11.0 | 4.6 | 0.4 | −30.3% |
| 2021 | 2.5 | -14.3 | 1.7 | 1.0 | 11.9 | 6.4 | 18.0 | 1.4 | -6.2 | 2.1 | 3.0 | 10.4 | +40.1% |
| 2020 | -4.8 | -6.5 | -12.9 | 20.3 | 11.0 | -2.4 | 21.2 | -1.0 | 6.6 | 3.2 | 2.7 | 7.9 | +47.8% |
| 2019 | 15.2 | 4.0 | 2.3 | -0.5 | -9.9 | 11.6 | -10.6 | -4.0 | 3.0 | 0.9 | 8.1 | 4.5 | +23.6% |
| 2018 | 9.6 | -4.8 | -0.8 | -3.1 | 1.3 | -1.5 | 8.1 | 16.7 | 5.2 | -11.1 | 0.7 | -9.8 | +7.4% |
| 2017 | 2.0 | 2.0 | 7.0 | 2.3 | 6.1 | 8.1 | -3.4 | 1.8 | 3.0 | 4.9 | 1.9 | -0.8 | +40.2% |
| 2016 | -9.8 | -2.2 | 4.7 | 1.9 | 8.6 | -4.3 | 8.6 | -6.4 | 5.4 | -9.3 | -0.3 | 2.8 | −2.7% |
| 2015 | 4.5 | 2.8 | 8.8 | 0.2 | 2.9 | -0.2 | 0.5 | -8.0 | -5.6 | 12.4 | 2.9 | 0.8 | +22.5% |
| 2014 | 5.7 | 3.9 | -0.6 | -6.9 | 7.1 | 4.2 | -1.3 | -3.0 | -2.8 | -0.4 | 4.7 | -3.8 | +6.1% |
| 2013 | 11.0 | -3.0 | -1.6 | -8.9 | 2.2 | 3.8 | 4.9 | 5.5 | 4.9 | 0.8 | 0.0 | 8.4 | +29.9% |
| 2012 | 19.9 | 12.6 | 2.4 | -0.2 | -3.6 | -3.0 | -1.0 | 6.8 | 7.9 | 5.0 | 2.3 | 0.3 | +58.7% |
| 2011 | -0.9 | 3.6 | -0.9 | 7.6 | -2.1 | -2.8 | -9.1 | -6.5 | -16.0 | 7.6 | -8.5 | 5.7 | −22.5% |
| 2010 | -2.2 | 10.3 | 7.6 | 4.8 | -9.4 | -8.9 | -5.9 | 8.0 | 10.1 | 1.3 | -0.6 | 10.8 | +25.4% |
| 2009 | -9.3 | 2.1 | -0.9 | 14.1 | 11.7 | 6.9 | 1.3 | 3.5 | 5.4 | -3.3 | 1.4 | 9.1 | +48.0% |
| 2008 | -4.6 | 0.0 | -2.3 | 9.5 | 6.5 | -1.5 | 4.5 | -2.4 | -12.1 | -28.2 | 0.7 | -23.0 | −46.5% |
| 2007 | 7.4 | -0.5 | 2.0 | -0.1 | 9.5 | -1.7 | 6.8 | -1.5 | 6.6 | -5.8 | -0.9 | -4.6 | +17.0% |